Triptolide inhibits MDM2 and induces apoptosis in acute lymphoblastic leukemia cells through a p53-independent pathway

Molecular Cancer Therapeutics

Volumn 12, Issue 2, 2013, Pages 184-194

  Huang, Mei ^a   Zhang, Hailong ^a   Liu, Tao ^a   Tian, Dan ^a   Gu, Lubing ^a   Zhou, Muxiang ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; MESSENGER RNA; PROTEIN MDM2; PROTEIN P53; TRIPTOLIDE; X LINKED INHIBITOR OF APOPTOSIS;

ACUTE LYMPHOBLASTIC LEUKEMIA; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CELL STRESS; CONTROLLED STUDY; DNA DAMAGE; DOWN REGULATION; G1 PHASE CELL CYCLE CHECKPOINT; HUMAN; HUMAN CELL; MESSENGER RNA SYNTHESIS; PRIORITY JOURNAL;

ANTINEOPLASTIC AGENTS, ALKYLATING; APOPTOSIS; CHILD; DITERPENES; EPOXY COMPOUNDS; HUMANS; PHENANTHRENES; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PROMOTER REGIONS, GENETIC; PROTO-ONCOGENE PROTEINS C-MDM2; SIGNAL TRANSDUCTION; TRANSFECTION; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84874100498     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-12-0425     Document Type: Article

References (46)

1. Tao XL, Sun Y, Dong Y, Xiao YL, Hu DW, Shi YP, et al. A prospective, controlled, double-blind, cross-over study of Tripterygium wilfodii hook F in treatment of rheumatoid arthritis. Chin Med J (Engl) 1989; 102:327-32.
2. Jiang X. Clinical observations on the use of the Chinese herb Tripterygium wilfordii Hook for the treatment of nephrotic syndrome. Pediatr Nephrol 1994; 8:343-4.
3. Qin WZ, Zhu GD, Yang SM, Han KY, Wang J. Clinical observations on Tripterygium wilfordii in treatment of 26 cases of discoid lupus erythematosus. J Tradit Chin Med 1983; 3:131-2.
4. Shamon LA, Pezzuto JM, Graves JM, Mehta RR, Wangcharoentrakul S, Sangsuwan R, et al. Evaluation of the mutagenic, cytotoxic, and antitumor potential of triptolide, a highly oxygenated diterpene isolated from Tripterygium wilfordii. Cancer Lett 1997; 112:113-7.
5. Kiviharju TM, Lecane PS, Sellers RG, Peehl DM. Antiproliferative and proapoptotic activities of triptolide (PG490), a natural product entering clinical trials, on primary cultures of human prostatic epithelial cells. Clin Cancer Res 2002; 8:2666-74.
6. Yang S, Chen J, Guo Z, Xu XM, Wang L, Pei XF, et al. Triptolide inhibits the growth and metastasis of solid tumors. Mol Cancer Ther 2003; 2:65-72.
7. Wang W, Yang S, Su Y, Xiao Z, Wang C, Li X, et al. Enhanced antitumor effect of combined triptolide and ionizing radiation. Clin Cancer Res 2007; 13:4891-9.
8. MujumdarN, Mackenzie TN, DudejaV, Chugh R, Antonoff MB, BorjaCacho D, et al. Triptolide induces cell death in pancreatic cancer cells by apoptotic and autophagic pathways. Gastroenterology 2010; 139: 598-608.
9. Kitzen JJ, de Jonge MJ, Lamers CH, Eskens FA, van der Biessen D, van Doorn L, et al. Phase I dose-escalation study of F60008, a novel apoptosis inducer, in patients with advanced solid tumours. Eur J Cancer 2009; 45:1764-72.
10. Yinjun L, Jie J, Yungui W. Triptolide inhibits transcription factor NFkappaB and induces apoptosis of multiple myeloma cells. Leuk Res 2005; 29:99-105.
11. Zhu W, Ou Y, Li Y, Xiao R, Shu M, Zhou Y, et al. A small-molecule triptolide suppresses angiogenesis and invasion of human anaplastic thyroid carcinoma cells via down-regulation of the nuclear factor-kappa B pathway. Mol Pharmacol 2009; 75: 812-9.
12. Lou YJ, Jin J. Triptolide down-regulates bcr-abl expression and induces apoptosis in chronic myelogenous leukemia cells. Leuk Lymphoma 2004; 45:373-6.
13. Shi X, Jin Y, Cheng C, Zhang H, Zou W, Zheng Q, et al. Triptolide inhibits Bcr-Abl transcription and induces apoptosis in STI571-resistant chronic myelogenous leukemia cells harboring T315I mutation. Clin Cancer Res 2009; 15:1686-97.
14. Saluja A, Dudeja V. Heat shock proteins in pancreatic diseases. J Gastroenterol Hepatol 2008; 23 Suppl 1:S42-5.
15. Phillips PA, Dudeja V, McCarroll JA, Borja-Cacho D, Dawra RK, Grizzle WE, et al. Triptolide induces pancreatic cancer cell death via inhibition of heat shock protein 70. Cancer Res 2007; 67: 9407-16.
16. Titov DV, Gilman B, He QL, Bhat S, Low WK, Dang Y, et al. XPB, a subunit of TFIIH, is a target of the natural product triptolide. Nat Chem Biol 2011; 7:182-8.
17. Vispe S, DeVries L, Creancier L, Besse J, Breand S, Hobson DJ, et al. Triptolide is an inhibitor of RNA polymerase I and II-dependent transcription leading predominantly to down-regulation of short-lived mRNA. Mol Cancer Ther 2009; 8:2780-90.
18. Momand J, Zambetti GP, Olson D, George D, Levine AJ. The MDM-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell 1992; 69: 1237-45.
19. Honda R, Tanaka H, Yasuda H. Oncoprotein MDM2 is a ubiquitin ligase E3 for tumor suppressor p53. FEBS Lett 1997; 420:25-7.
20. Xiao ZX, Chen J, Levine AJ, Modjtahedi N, Xing J, Sellers WR, et al. Interaction between the retinoblastoma protein and the oncoprotein MDM2. Nature 1995; 375:694-8.
21. Zhang Z, Wang H, Li M, Rayburn ER, AgrawalS, Zhang R. Stabilization of E2F1 protein by MDM2 through the E2F1 ubiquitination pathway. Oncogene 2005; 24:7238-47.
22. Gu L, Findley HW, Zhou M. MDM2 induces NF-kB/p65 expression transcriptionally through Sp1-binding sites: A novel, p53-independent role of MDM2 in adriamycin resistance in acute lymphoblastic leukemia. Blood 2002; 99:3367-75.
23. Elenbaas B, Dobbelstein M, Roth J, Shenk T, Levine AJ. The MDM2 oncoprotein binds specifically to RNA through its RING finger domain. Mol Med 1996; 2:439-51.
24. Gu L, Zhu N, Zhang H, Durden DL, Feng Y, Zhou M. Regulation of XIAP translation and induction by MDM2 following irradiation. Cancer Cell 2009; 15:363-75.
25. Oliner JD, Kinzler KW, Meltzer PS, George DL, Vogelstin B. Amplification of a gene encoding a p53-associated protein in human sarcomas. Nature 1992; 358:80-8.
26. Momand J, Jung D, Wilczynski S, Niland J. The MDM2 gene amplification database. Nucleic Acids Res 1998; 26:3453-9.
27. Bueso-Ramos CE, Yang Y, deLeon E, McCown P, Stass SA, Albitar M. The human MDM-2 oncogene is overexpressed in leukemias. Blood 1993; 82:2617-23.
28. Cattelani S, Defferrari R, Marsilio S, Bussolari R, Candini O, Corradini F, et al. Impact of a single nucleotide polymorphism in the MDM2 gene on neuroblastoma development and aggressiveness: results of a pilot study on 239 patients. Clin Cancer Res 2008; 14: 3248-53.
29. Zhou M, Yeager AM, Smith SD, Findley HW. Overexpression of the MDM2 gene by childhood acute lymphoblastic leukemia cells expressing the wild-type p53 gene. Blood 1995; 85: 1608-14.
30. Gustafsson B, Stal O, Gustafsson B. Overexpression of MDM2 inacute childhood lymphoblastic leukemia. Pediatr Hematol Oncol 1998; 15: 519-26.
31. Zhou M, Gu L, Abshire T, Homans A, Yeager AM, Findley HW. Incidence and prognostic significance of MDM2 oncoprotein overexpression in relapsed childhood acute lymphoblastic leukemia. Leukemia 2000; 14:61-7.
32. Marks DI, Kurz BW, Link MP, Ng E, Shuster JJ, Lauer SJ, et al. High incidence of potential p53 inactivation in poor outcome childhood acute lymphoblastic leukemia at diagnosis. Blood 1996; 87: 1155-61.
33. Marks DI, Kurz BW, Link MP, Ng E, Shuster JJ, Lauer SJ, et al. Altered expression of p53 and mdm-2 proteins at diagnosis is associated with early treatment failure in childhood acute lymphoblastic leukemia. J Clin Oncol 1997; 15:1158-62.
34. Gustafsson B, Christenson B, Hjalmar V, Winiarski J. Cellular expression of MDM2 and p53 in childhood leukemias with poor prognosis. Med Pediatr Oncol 2000; 34:117-24.
35. Gustafsson B, Axelsson B, Gustafsson B, Christensson B, Winiarski J. MDM2 and p53 in childhood acute lymphoblastic leukemia: higher expression in childhood leukemias with poor prognosis compared to long-term survivors. Pediatr Hematol Oncol 2001; 18:497-508.
36. Findley WH, Gu L, Yeager AM, Zhou M. Expression and regulation of Bcl-2, Bcl-xl and Bax correlate with p53 status and sensitivity to apoptosis in childhood acute lymphoblastic leukemia. Blood 1997; 89:2986-93.
37. Zhou M, Gu L, Findley HW, Jiang R, Woods WG. PTEN reverses MDM2-mediated chemotherapy resistance by interacting with p53 in acute lymphoblastic leukemia cells. Cancer Res 2003; 63: 6357-62.
38. Zhu N, Gu L, Li F, Zhou M. Inhibition of the Akt/survivin pathway synergizes the antileukemia effect of nutlin-3 in acute lymphoblastic leukemia cells. Mol Cancer Ther 2008; 7:1101-9.
39. Zhang X, Gu L, Li J, Shah N, He J, Yang L, et al. Degradation of MDM2 by the interaction between berberine and DAXX leads to potent apoptosis in MDM2-overexpressing cancer cells. Cancer Res 2010; 70:9895-904.
40. Canman CE, LimDS, Cimprich KA, Taya Y, Tamai K, Sakaguchi K, et al. Activation of the ATM kinase by ionizing radiation and phosphorylation of p53. Science 1998; 281:1677-9.
41. Choi YJ, Kim TG, Kim YH, Lee SH, Kwon YK, Suh SI, et al. Immunosuppressant PG490 (triptolide) induces apoptosis through the activation of caspase-3 and down-regulation of XIAP in U937 cells. Biochem Pharmacol 2003; 66:273-80.
42. Eckelman BP, Salvesen GS, Scott FL. Human inhibitor of apoptosis proteins: why XIAP is the black sheep of the family. EMBO Rep 2006; 7:988-94.
43. Carter BZ, Mak DH, Schober WD, McQueen T, Harris D, Estrov Z, et al. Triptolide induces caspase-dependent cell death mediated via the mitochondrial pathway in leukemic cells. Blood 2006; 108:630-7.
44. Chang WT, Kang JJ, Lee KY, Wei K, Anderson E, Gotmare S, et al. Triptolide and chemotherapy cooperate in tumor cell apoptosis. A role for the p53 pathway. J Biol Chem 2001; 276:2221-7.
45. Okamoto K, Li H, Jensen MR, Zhang T, Taya Y, Thorgeirsson SS, et al. Cyclin G recruits PP2A to dephosphorylate Mdm2. Mol Cell 2002; 9:761-71.
46. Meek DW, Knippschild U. Posttranslational modification of MDM2. Mol Cancer Res 2003; 1:1017-26. 1014.